Clinical Trial

VCA Regimen Followed by D-MAG Regimen on the Treatment of Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The purpose of this study is to evaluate the safety and efficacy of Venetoclax Combining Chidamide and Azacitidine (VCA) Followed by D-MAG Regimen on the Treatment of Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2022-10-29; most recent amendment 2025-02-18.
Status change: Not Yet Recruiting → Recruiting 2023-12-07
Trial Details
NCT Number NCT05603884
Lead Sponsor The First Affiliated Hospital of Xiamen University
Collaborators: Chipscreen Biosciences, Ltd., CSPC Pharmaceutical Group Limited, Fujian Provincial Hospital, Fujian Cancer Hospital, Zhangzhou manicipal hospital of Fujian Province, Jieyang People's Hospital, Huizhou Municipal Central Hospital
Conditions Leukemia, Myeloid, Acute, AML Stage, Adult
Enrollment 66 participants
Start Date 2022-12-01
Primary Completion 2026-12-31 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2025-02-19